Volume 375, Issue 9722, Pages (April 2010)

Slides:

Advertisements

Similar presentations

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Advertisements

Treatment of Stage I and II Non-small Cell Lung Cancer

Volume 355, Issue 9212, Pages (April 2000)

Su K. Metcalfe, MD, MPH, Michael T

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Volume 376, Issue 9747, Pages (October 2010)

Volume 383, Issue 9928, Pages (May 2014)

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis K.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Volume 378, Issue 9804, Pages (November 2011)

Volume 13, Issue 12, Pages (December 2012)

Volume 366, Issue 9503, Pages (December 2005)

Treatment of Stage I and II Non-small Cell Lung Cancer

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Aspirin in the prevention of cancer – Author's reply

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Volume 14, Issue 7, Pages (June 2013)

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Adjuvant chemotherapy for rectal cancer – Authors' reply

Volume 12, Issue 7, Pages (July 2011)

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A.

Volume 386, Issue 10001, Pages (October 2015)

Volume 13, Issue 12, Pages (December 2012)

Treatment of Stage I and II Non-small Cell Lung Cancer

Volume 386, Issue 10001, Pages (October 2015)

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Volume 18, Issue 3, Pages (March 2017)

Volume 385, Issue 9962, Pages (January 2015)

Leora Horn, MD, MSc, FRCPC, Alan B. Sandler, MD, Joe B

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Volume 371, Issue 9627, Pages (May 2008)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Volume 9, Issue 4, Pages (April 2008)

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Volume 373, Issue 9658, Pages (January 2009)

Volume 383, Issue 9928, Pages (May 2014)

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Volume 373, Issue 9658, Pages (January 2009)

Volume 375, Issue 9719, Pages (March 2010)

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Volume 11, Issue 3, Pages (March 2010)

Volume 373, Issue 9672, Pages (April 2009)

Volume 383, Issue 9921, Pages (March 2014)

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Volume 376, Issue 9747, Pages (October 2010)

Volume 12, Issue 1, Pages (January 2011)

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of.

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Primary Small Cell Carcinoma of the Esophagus

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Volume 20, Issue 8, Pages (August 2019)

Presentation transcript:

Volume 375, Issue 9722, Pages 1267-1277 (April 2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non- small-cell lung cancer: two meta-analyses of individual patient data The Lancet Volume 375, Issue 9722, Pages 1267-1277 (April 2010) DOI: 10.1016/S0140-6736(10)60059-1 Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 1 Effect of surgery (S) and chemotherapy (CT) versus surgery on survival, by type of chemotherapy Every trial is represented by a square, the center of which denotes the hazard ratio (HR) for that trial comparison with the horizontal lines showing the 95% and 99% CIs. The size of the square is directly proportional to the amount of information contributed by the trial. The open diamonds represent pooled HRs for the trial groups, with the centre denoting the HR and the extremities the 95% CI. The black diamond gives the pooled hazard ratio from the fixed effect model, without double counting the control groups of the three-grouped trials WJSG2 and ACTLC4. The centre of this diamond denotes the HR and the extremities the 95% CI. The control groups of the three-grouped trials WJSG2 and ACTLC4 are included only once in the total events and patients and in the overall analysis. O–E=observed minus expected. IPCR=Institute of Pulmonary Cancer Research, Chiba. JLCSSG=Japan Lung Cancer Surgical Study Group. ALPI=Adjuvant Lung Cancer Project. IALT=International Adjuvant Lung Trial. BLT=Big Lung Trial. JCOG=Japan Clinical Oncology Group. ANITA=Adjuvant Navelbine International Trialist Association. CALGB=Cancer and Leukemia Group B. LCSG=Lung Cancer Study Group. FLCSG=Finnish Lung Cancer Study Group. SGACLC=Study Group of Adjuvant Chemotherapy for Lung Cancer. OLCSG=Osaka Lung Cancer Study Group. WJSG=West Japan Study Group for Lung Cancer Surgery. ACTLC=Study Group of Adjuvant Chemotherapy for Lung Cancer. NJSGLCS=North-east Japan Study Group for Lung Cancer. JLCRG=Japan Lung Cancer Research Group. The Lancet 2010 375, 1267-1277DOI: (10.1016/S0140-6736(10)60059-1) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 2 Simple (non-stratified) Kaplan-Meier curves for trials of surgery (S) and chemotherapy (CT) versus surgery alone and for trials of surgery and chemotherapy and radiotherapy (RT) versus surgery and radiotherapy The Lancet 2010 375, 1267-1277DOI: (10.1016/S0140-6736(10)60059-1) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 3 Exploratory analyses of the effect of surgery (S) and chemotherapy (CT) versus surgery on survival, by use of tegafur plus uracil or tegafur and by stage and performance status HR=hazard ratio. O–E=observed minus expected. PS=performance status. The Lancet 2010 375, 1267-1277DOI: (10.1016/S0140-6736(10)60059-1) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 4 Effect of surgery (S) and radiotherapy (RT) and chemotherapy (CT) versus surgery and radiotherapy on survival by type of chemotherapy HR=hazard ratio. O–E=observed minus expected. MSKCC=Memorial Sloan Kettering Cancer Center. GETCB=Groupe d'Etude et de Traitement des Cancers Bronchiques. MDA DM=MD Anderson Department of Medicine. Int=Intergroup. ALPI=Adjuvant Lung Cancer Project Italy. IALT=International Adjuvant Lung Trial. BLT=Big Lung Trial. ANITA=Adjuvant Navelbine International Trialist Association. LCSG=Lung Cancer Study Group. FLCSG=Finnish Lung Cancer Study Group. OLCSG=Osaka Lung Cancer Study Group. The Lancet 2010 375, 1267-1277DOI: (10.1016/S0140-6736(10)60059-1) Copyright © 2010 Elsevier Ltd Terms and Conditions